Is ICLR a good stock to buy? We came across a bullish thesis on ICON Public Limited Company on Value & Error’s Substack. In this article, we will summarize the bulls’ thesis on ICLR. ICON Public Limited Company’s share was trading at $101.28 as of March 24th. ICLR’s trailing and forward P/E were 13.44 and 8.22 respectively according to Yahoo Finance.
Looker_Studio/Shutterstock.com
ICON plc (NASDAQ: ICLR) is a leading Clinical Research Organization (CRO) that plays a critical role in the pharmaceutical value chain by managing outsourced clinical trials for drug developers. These services are essential, creating long-term client relationships, recurring revenue streams, and substantial backlog visibility.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
However, the stock declined sharply by nearly 40% following the announcement of an accounting probe tied to revenue recognition issues impacting roughly 2% of FY23 and FY24 revenues, raising concerns around financial reporting integrity and near-term uncertainty.
Even prior to this development, investor sentiment had been weakening due to cyclical pressures across the CRO industry, including trial cancellations, project delays, pricing pressure, and a slowdown in outsourcing growth. These factors contributed to expectations of softer near-term performance despite the company’s structurally attractive position within the healthcare ecosystem. The accounting issue has further amplified these concerns, creating a significant dislocation between fundamentals and market perception.
At current levels, ICON trades at approximately 6.5x earnings, reflecting a deeply discounted valuation relative to its historical multiples and underlying cash flow generation. The business continues to produce over $1 billion in free cash flow annually, supported by its entrenched customer base and mission-critical services. Additionally, an active share repurchase program signals management’s confidence in intrinsic value and provides a potential floor for the stock.
While the accounting probe introduces headline risk and may weigh on sentiment in the near term, the limited financial impact suggests the core business remains intact. If resolved without broader implications, the current valuation presents a compelling opportunity for investors willing to underwrite temporary uncertainty in exchange for strong long-term fundamentals.
Previously, we covered a bullish thesis on ICON Public Limited Company (ICLR) by DeepValue Capital in May 2025, which highlighted its strong backlog, structural tailwinds from rising clinical trial demand, and long-term upside driven by pharma R&D growth. ICLR’s stock price has depreciated by approximately 30.15% since our coverage after the announcement of an accounting probe tied to revenue recognition. Value & Error shares a similar view but emphasizes on near-term uncertainty driven by an accounting probe and cyclical industry pressures.
ICON Public Limited Company is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 41 hedge fund portfolios held ICLR at the end of the fourth quarter which was 43 in the previous quarter. While we acknowledge the risk and potential of ICLR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ICLR and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
